ReviewLife sciences2021
Targeting inflammatory cytokine storm to fight against COVID-19 associated severe complications.
Review in Life sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 2 syntheses or guidelines pooled it, 49 citations in OpenAlex.
- Pooled it
- Serum hydroxybutyrate dehydrogenase and COVID-19 severity and mortality: a systematic review and meta-analysis with meta-regression.Clinical and experimental medicine · 2022Pooled it
- Chemical characterization of Jing Guan Fang and its application in alleviating coronavirus envelope protein-induced proinflammatory responsesJournal of traditional and complementary medicine · 2026Article
- Dual antiviral and anti-inflammatory effects of BAY 11-7082 in SARS-CoV-2 infection via inhibition of the canonical NF-κB signaling pathway.Scientific reports · 2026Article
- Modeling "Two-Hit" Severe Pneumonia in Mice: Pathological Characteristics and Mechanistic Studies.Inflammation · 2025Article
- Exploring serum and glucocorticoid-regulated kinase 1: A promising target for COVID-19 and atrial fibrillation treatment.Heart rhythm O2 · 2025Review
- Novel therapeutic effects of rifaximin in combination with methylprednisolone for LPS-induced oxidative stress and inflammation in mice: AnToxicology reports · 2024Article
- Prospective Variation of Cytokine Trends during COVID-19: A Progressive Approach from Disease Onset until Outcome.International journal of molecular sciences · 2024Article
- Advances in nano-based drug delivery systems for the management of cytokine influx-mediated inflammation in lung diseases.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- The impact understanding of exosome therapy in COVID-19 and preparations for the future approaches in dealing with infectious diseases and inflammation.Scientific reports · 2024Article
- Article
- Multi-organ microphysiological system: A new paradigm for COVID-19 research.Organs-on-a-chip · 2023Article
- Transforming growth factor beta 1 (TGF-β1) in COVID-19 patients: relation to platelets and association with the disease outcome.Molecular and cellular biochemistry · 2023Article
- Molecular mechanisms of COVID-19-induced pulmonary fibrosis and epithelial-mesenchymal transition.Frontiers in pharmacology · 2023Review
- Highlights on molecular targets in the management of COVID-19: Possible role of pharmacogenomics.The Journal of international medical research · 2023Review
- Long-term Complications of COVID-19 in Nursing Staff; a Retrospective Longitudinal Study.Archives of academic emergency medicine · 2023Article
- COVID-19 and fibrosis: Mechanisms, clinical relevance, and future perspectives.Drug discovery today · 2022Review
- The effects of high dose vitamin D supplementation as a nutritional intervention strategy on biochemical and inflammatory factors in adults with COVID-19: Study protocol for a randomized controlled trial.Nutrition and health · 2022Article
- Pathological Features and Neuroinflammatory Mechanisms of SARS-CoV-2 in the Brain and Potential Therapeutic Approaches.Biomolecules · 2022Review
- Cytokine producing ability of peripheral blood cells from COVID-19 patients after unspecific in vitro stimulation.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Such testing and trying time probably never seen before in the human history. The novel coronavirus disease abbreviated as COVID-19 is the ongoing health crisis which entered into human life in late December 2019. The ease of transmission between humans and the undetectability in early stage makes COVID-19 frightening and unprecedented. The disease is characterised by pneumonia progressing to breathing difficulty, acute respiratory distress syndrome (ARDS) and multi-organ failure. Clinical studies suggest excessive release of inflammatory mediators leads to cytokine storm, a phenomenon which appears to be potentially life-threatening in COVID-19. Across the globe, when the world authorities are grappling to contain the virus, our review provides a glimpse on structure, pathophysiology of the virus and further sheds light on various clinical complications associated with the disease in order to open up/raise new horizons to explore various possible theoretical targets for COVID-19. The review also portrays a question and debates: Can targeting cytokine storm can be a feasible approach to combat COVID-19?
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.